REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock.

Latest Upgrades and Downgrades for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
—	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$2→$1
—	Alliance Global Partners	James Molloy	PT Raise	Buy	$16→$30
—	D. Boral Capital	Jason Kolbert	Downgrade	Buy→Hold	—
—	Chardan Capital	Keay Nakae	Maintained	Buy	$40
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$40
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$80
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$40
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$40
—	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$220→$80
—	Chardan Capital	Rudy Li	Initiate	Buy	$40
—	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$60→$40
—	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$280→$140
—	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$140→$60
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$60
—	Maxim Group	Jason McCarthy	PT Cut	Buy	$100→$40
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$60
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$60
—	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$160→$60
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$160

Analyst Ratings News

PRO
Maxim Group Downgrades Reviva Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.

Benzinga Newsdesk

PRO
Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Benzinga Newsdesk

PRO
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

D. Boral Capital analyst Jason Kolbert downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

Benzinga Newsdesk

REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc.

REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Price Target 2026

Latest Upgrades and Downgrades for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. Stock

REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Price Target 2026

Latest Upgrades and Downgrades for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. Stock

Analyst Ratings News

PROMaxim Group Downgrades Reviva Pharmaceuticals to Hold

PROWatching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

PROD. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

PROD. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PROD. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PROD. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

Analyst Ratings News

PROMaxim Group Downgrades Reviva Pharmaceuticals to Hold

PROWatching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

PROD. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

PROD. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PROD. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PROD. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PRO
Maxim Group Downgrades Reviva Pharmaceuticals to Hold

PRO
Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

PRO
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PRO
Maxim Group Downgrades Reviva Pharmaceuticals to Hold

PRO
Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

PRO
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target